Letter to the Editor|Volume 8, Issue 2|pp 208—209 The longevity transporter mIndy (Slc13a5) as a target for treating hepatic steatosis and insulin resistance
Diana M. Willmes1,Section of Metabolic Vascular Medicine, Medical Clinic III, Dresden University School of Medicine, Technische Universität Dresden, Dresden, Germany2Paul Langerhans Institute Dresden (PLID), German Center for Diabetes Research (DZD), Dresden, Germany, Stephen L. Helfand3Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI 02912, USA, Andreas L. Birkenfeld1,Section of Metabolic Vascular Medicine, Medical Clinic III, Dresden University School of Medicine, Technische Universität Dresden, Dresden, Germany2Paul Langerhans Institute Dresden (PLID), German Center for Diabetes Research (DZD), Dresden, Germany
- 1Section of Metabolic Vascular Medicine, Medical Clinic III, Dresden University School of Medicine, Technische Universität Dresden, Dresden, Germany
- 2Paul Langerhans Institute Dresden (PLID), German Center for Diabetes Research (DZD), Dresden, Germany
- 3Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI 02912, USA
Received: February 19, 2016Published: February 23, 2016
Copyright: © 2016 Willmes et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
